STAT3 and neoplasm: Another study comparing mutations in synchronous/metachronous metastases with primary breast tumors demonstrated additional mutations in metastases, particularly loss of JAK2 and STAT3, suggesting that the JAK/STAT3 pathway may function as a tumor suppressor and explain the improved short and long-term outcomes in these patients [121].